Extended indication Kinpeygo is indicated for the treatment of adults with a urine protein excretion-to-creatinine ratio
Therapeutic value Possible added value for a subgroup
Total cost 34,650,000.00
Registration phase Registered

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information